Skip to content
Menu

GRAIL, Inc. GRAL

Full chart Compare
Set alert

Price alert · GRAL

All alert types
99.25 USD -5.59 (-5.33%)

Regular-session close

99.25 0.00 0.00%

After hours · Nov 20, 4:20 PM ET

98.36 Day range 103.96
41.50 52-week range 166.48
YTD
+15.96%
1 year
+15.88%

5D -11.76 (-10.48%)

100105110MonTueWedThuFri100.48
Market cap
4.46B
Revenue (ttm)
166.60M
Profit margin
-243.80%
EPS (ttm)
-9.22
Shares out
44.96M
Forward P/E
-12.19
YTD return
+15.96%
1-year return
+15.88%
50-day average
123.51
200-day average
79.31
Volume
733.72K
Avg volume
1.03M
Open
100.93
Previous close
104.84
Day's range
98.36 – 103.96
52-week range
41.50 – 166.48
Beta
2.87
Analysts
Buy
Price target
139.44 (+40.5%)
Earnings date
Feb 18, 2027

Key statistics

Enterprise value
4.01B
Price / sales
26.79
Price / book
1.81
Revenue growth
3.70%
Free cash flow
-112.64M
Total cash
788.68M
Total debt
85.85M
Return on equity
-17.31%
Short % of float
18.16%

Fundamental scorecard

6 of 25 checks passed on GRAL’s reported financials

ValueGrowthProfitabilityHealthDividend

6of 25 checks passed

  • Value 0 of 5
  • Growth 2 of 5
  • Profitability 1 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
GRAL Revenue — quarterly 37.53M
GRAL Net income — quarterly -103.57M
GRAL EPS — quarterly -2.21

Earnings

GRAL recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 18, 2027Dec 30, 2026-2.38———
Nov 4, 2026Sep 30, 2026-2.56-2.21+0.35+13.67%
Aug 5, 2026Jun 30, 2026-2.66-2.56+0.10+3.76%
May 5, 2026Mar 31, 2026-2.76-2.29+0.47+17.11%
Feb 19, 2026Dec 31, 2025-3.33-2.44+0.89+26.73%
Nov 12, 2025Sep 30, 2025-3.36-2.46+0.90+26.79%

Upgrades / downgrades

GRAL analyst upgrades and downgrades
DateFirmActionFromTo
Nov 10, 2026Piper SandlermainNeutralNeutral
Nov 5, 2026RBC CapitalmainSector PerformSector Perform
Oct 13, 2026Morgan StanleymainEqual-WeightEqual-Weight
Oct 13, 2026TD CowenmainBuyBuy
Oct 2, 2026UBSmainBuyBuy
Oct 1, 2026GuggenheimmainBuyBuy

About GRAIL, Inc.

GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Sunnyvale, California.

Sector
Healthcare
Industry
Diagnostics & Research
Country
United States
Website
grail.com

News

Your note

Sign in to keep a note on GRAL — it syncs with the Stock Master app.

Insider holders

GRAL insider holders
InsiderRelationLatest transactionDateShares held
CHASE WILLIAM JDirectorStock Award(Grant)Oct 14, 202643,131
DING CHUN RBeneficial Owner of more than 10% of a Class of SecuritySaleJun 30, 20250
FREIDIN AARONChief Financial OfficerSaleNov 15, 2026222,364
ILLUMINA INCBeneficial Owner of more than 10% of a Class of SecuritySaleNov 16, 20253,502,130
KREVANS SARAHDirectorStock Award(Grant)Jun 21, 202642,628
MIZELL STEVENDirectorStock Award(Grant)Oct 14, 202642,978

Institution ownership

GRAL institution ownership
Holder% heldSharesValueReported
Farallon Capital Management LLC9.05%4,069,233403.87MSep 29, 2026
Baker Bros. Advisors, LP8.96%4,028,614399.84MSep 29, 2026
Blackrock Inc.8.52%3,830,649380.19MSep 29, 2026
Primecap Management Company4.94%2,221,250220.46MSep 29, 2026
State Street Corporation4.48%2,015,422200.03MSep 29, 2026
Vanguard Capital Management LLC4.10%1,845,134183.13MSep 29, 2026

Fund ownership

GRAL fund ownership
Holder% heldSharesValueReported
PRIMECAP Odyssey Funds-PRIMECAP Odyssey Aggressive Growth Fund3.51%1,579,791156.79MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.73%1,228,548121.93MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.38%1,068,030106.00MSep 29, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF2.18%979,35197.20MSep 29, 2026
Fidelity Salem Street Trust-Fidelity Small Cap Index Fund1.01%452,48344.91MAug 30, 2026
iShares Trust-iShares Russell 2000 Value ETF0.86%387,26438.44MSep 29, 2026